Summary
21 / 100 · Bulios Score
What speaks for it
- It earns 22 USD a year on every 100 USD of invested capital.
- The price moves less than the market (beta 0.67).
What to watch
- Revenue fell by 21% a year over the last 3 years.
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
Revenue fell by 21% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2015By product
The company reports no revenue by product.
By region
- Asia 66%
- Other 27%
- United States 6.4%
- Canada 1.3%
- Europe 0.1%
Asia brings in 66% of revenue.
Segments in detail